Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 8085587

Decrease in normal human corneal sensitivity with topical diclofenac sodium.

K Szerenyi·K Sorken·J J Garbus·M Lee·P J McDonnell
View original source ↗Export metadata ↓

Abstract

We tested the effect of topical diclofenac sodium on corneal sensitivity in the human eye. Corneal sensitivity was measured in ten adult subjects with the Cochet-Bonnet esthesiometer before, and immediately after, applying one drop of diclofenac sodium 0.1% in one eye and one drop of diclofenac vehicle in the other eye. Application was repeated every five minutes for 20 minutes; then no more drops were applied, and corneal sensitivity was measured every 15 minutes until sensitivity measurements returned to baseline levels. Diclofenac sodium decreased corneal sensitivity significantly (P = .0001) in all ten subjects, compared with eyes treated with the vehicle. The effect of diclofenac sodium increased as additional drops were administered. After the drug instillation was stopped, corneal sensitivity returned to baseline measurements within less than an hour in all the subjects. Diclofenac sodium substantially lowers sensitivity in normal, unoperated-on human corneas; the vehicle has no measurable effect on sensitivity.

Explore related subjects

Administration, TopicalAdultAnalysis of VarianceCorneaDiclofenacHumansOphthalmic SolutionsOphthalmologyTrigeminal NerveClinical TrialJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Szerenyi, K Sorken, J J Garbus, M Lee, P J McDonnell. 1994-09-15. Decrease in normal human corneal sensitivity with topical diclofenac sodium.. https://doi.org/10.1016/s0002-9394(14)72954-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Collateral sprouting of uninjured primary afferent A-fibers into the superficial dorsal horn of the adult rat spinal cord after topical capsaicin treatment to the sciatic nerve.

That terminals of uninjured primary sensory neurons terminating in the dorsal horn of the spinal cord can collaterally sprout was first suggested by Liu and Chambers (1958), but this has since been disputed. Recently, horseradish peroxidase conjugated to the B subunit of cholera toxin (B-HRP) and intracellular HRP injections have shown that sciatic nerve section or crush produces a long-lasting rearrangement in the organization of primary afferent central terminals, with A-fibers sprouting into lamina II, a region that normally receives only C-fiber input (Woolf et al., 1992). The mechanism of this A-fiber sprouting has been thought to involve injury-induced C-fiber transganglionic degeneration combined with myelinated A-fibers being conditioned into a regenerative growth state. In this study, we ask whether C-fiber degeneration and A-fiber conditioning are both necessary for the sprouting of A-fibers into lamina II. Local application of the C-fiber-specific neurotoxin capsaicin to the sciatic nerve has previously been shown to result in C-fiber damage and degenerative atrophy in lamina II. We have used B-HRP to transganglionically label A-fiber central terminals and have shown that 2 weeks after topical capsaicin treatment to the sciatic nerve, the pattern of B-HRP staining in the dorsal horn is indistinguishable from that seen after axotomy, with lamina II displaying novel staining in the identical region containing capsaicin-treated C-fiber central terminals. These results suggest that after C-fiber injury, uninjured A-fiber central terminals can collaterally sprout into lamina II of the dorsal horn. This phenomenon may help to explain the pain associated with C-fiber neuropathy.

Administration, Topical↗
PubMed1996

Chronic, topical exposure to benzo[a]pyrene induces relatively high steady-state levels of DNA adducts in target tissues and alters kinetics of adduct loss.

Carcinogen-DNA adduct measurements may become useful biomarkers of effective dose and/or early effect. However, validation of this biomarker is required at several levels to ensure that human exposure and response are accurately reflected. Important in this regard is an understanding of the relative biomarker levels in target and nontarget organs and the response of the biomarker under the chronic, low-dose conditions to which humans are exposed. We studied the differences between single and chronic topical application of benzo[a]pyrene (BAP) on the accumulation and removal of BAP-DNA adducts in skin, lung, and liver. Animals were treated with BAP at 10, 25, or 50 nMol topically once or twice per week for as long as 15 weeks. Animals were sacrificed either at 24, 48, or 72 hr after the last dose at 1 and 30 treatments, and after 24 hr for all other treatment groups. Adduct levels increased with increasing dose, but the slope of the dose-response was different in each organ. At low doses, accumulation was linear in skin and lung, but at high doses the adduct levels in the lung increased dramatically at the same time when the levels in the skin reached apparent steady state. In the liver adduct, levels were lower than in target tissues and apparent steady-state adduct levels were reached rapidly, the maxima being independent of dose, suggesting that activating metabolism was saturated in this organ. Removal of adducts from skin, the target organ, was more rapid following single treatment than with chronic exposure. This finding is consistent with earlier data, indicating that some areas of the genome are more resistant to repair. Thus, repeated exposure and repair cycles would be more likely to cause an increase in the proportion of carcinogen-DNA adducts in repair-resistant areas of the genome. These findings indicate that single-dose experiments may underestimate the potential for carcinogenicity for compounds that follow this pattern.

Administration, Topical↗